Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis

Case Reports in Gastroenterology

Volumn 5, Issue 1, 2011, Pages 159-165

  Shimodate, Yuichi ^a   Takanashi, Kunihiro ^a   Waga, Eriko ^a   Fujita, Tomoki ^a   Katsuki, Shinichi ^a   Nomura, Masafumi ^b  

^a Otaru Ekisaikai Hospital   (Japan)

^b TEINE KEIJINKAI HOSPITAL   (Japan)

Author keywords

Diarrhea; Drug lymphocyte stimulation test; Mesalamine; Rechallenge trial; Side effect

Indexed keywords

C REACTIVE PROTEIN; MESALAZINE; METHYLPREDNISOLONE; PREDNISOLONE SODIUM PHOSPHATE; PREDONEMA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADOLESCENT; ANALYTIC METHOD; APHERESIS; ARTICLE; BLOODY DIARRHEA; CASE REPORT; COLONOSCOPY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG LYMPHOCYTE STIMULATION TEST; DRUG PULSE THERAPY; DRUG WITHDRAWAL; FEVER; GRANULOCYTE AND MONOCYTE ADSORPTIVE APHERESIS; HUMAN; MALE; MEDICAL HISTORY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 79957841123     PISSN: None     EISSN: 16620631     Source Type: Journal    
DOI: 10.1159/000326931     Document Type: Article

References (15)

1. Dick AP, Grayson MJ, Carpenter RG, et al: Controlled trial of sulfasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-442
2. Dissanayake AS, Truelove SC: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulafasalazine (Salazopyrin)Gut 1973;14:923-926
3. Azad Khan AK, Piris J, Truelove SC, et al: An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977;2:892-895
4. Peppercorn MA, Goldman P: The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972;181:555-562
5. Das KM, Eastwood MA, McManus JP, et al: Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-495
6. Haagen Nielsen O, Bondesen S: Kinetics of 5-aminosalicylic acid after jejuna instillation in man. Br J Clin Pharmacol 1983;16:738-740 (Pubitemid 14208220)
7. Schroeder KW, Tremainen WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629 (Pubitemid 18010466)
8. Hanauer SB, Sninsky CA, Robinson M, et al: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med 1993;118:540-549
9. Hanauer SB, Schwartz J, Robinson M, et al: Mesalamine capsules for treatment of active ulcerative colitis. Results of a controlled trial. Am J Gastroenterol 1993;88:1188-1197 (Pubitemid 23219711)
10. Miner P, Hanauer SB, Robinson M, et al: Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995;40:296-304
11. Marteau P, Nelet F, Lelu M, et al: Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996;10:949-956 (Pubitemid 26412924)
12. Fiorentini MT, Fracchia M, Galatola G, et al: Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci 1990;35:1180-1182 (Pubitemid 20289674)
13. +)-ATPase. A possible diarrhogenic factor? Clin Investig 1993;71:286-289 (Pubitemid 23106513)
14. Goldstein F, DiMarino AJ: Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease. J Clin Gastroenterol 2000;31:60-62 (Pubitemid 30430249)
15. Kapur KC, Williams GT, Allison MC, et al: Mesalazine induced exacerbation of ulcerative colitis. Gut 1995;37:838-839